A guide to TB-500's legal status in Arizona, covering FDA regulations, 503A/503B compounding rules, state pharmacy board rules, and how to access TB-500 legally.
A complete guide to TB-500's legal status in Oregon, covering FDA regulations, the 503A/503B compounding framework, the Oregon Board of Pharmacy, and what patients need to know before seeking a prescription.
A complete guide to TB-500's legal status in Tennessee, covering FDA regulations, 503A/503B compounding pharmacy rules, state pharmacy board requirements, and how patients can access thymosin beta-4 peptide legally through a licensed provider.
A complete guide to Egrifta (Tesamorelin) legal status in Louisiana, covering FDA approval, federal scheduling, 503A/503B compounding rules, Louisiana pharmacy board regulations, and how to obtain a legitimate prescription.
A complete guide to the legal status of Thymosin Alpha-1 in Colorado, covering FDA bulk-drug lists, 503A/503B compounding pharmacy rules, state pharmacy board requirements, and how to obtain a legitimate prescription.
A complete guide to FDA warning letters, USP <797> sterility standards, PCAB accreditation, and practical buyer guidance for sermorelin compounded peptides.
BPC-157 is not FDA-approved. This guide covers its 2026 compounding status, the advisory vote, the HHS draft policy, WADA rules and human evidence.
A breakdown of peptide prescription costs by compound, covering BPC-157, TB-500, GHK-Cu, CJC-1295/Ipamorelin, and insurance coverage realities for 2026.
A guide to micronized progesterone (Prometrium) safety for adults aged 30 to 49, covering clinical evidence, side effects, drug interactions, and dosing guidelines.
The Prometrium label says food raised progesterone bioavailability. Its only enzyme finding is in-vitro ketoconazole, and it does not mention grapefruit.
A clinician-level review of how micronized progesterone (Prometrium) is metabolized, how it affects thermogenesis and resting energy expenditure, and what the PEPI trial and mechanistic literature tell prescribers.
Micronized progesterone (Prometrium) after bariatric surgery presents unique absorption, dosing, and monitoring challenges. This clinical guide covers pharmacokinetics, evidence, and practical protocols for post-bariatric HRT.
A clinical deep-dive into micronized progesterone (Prometrium) use in special populations including solid-organ transplant recipients, people living with HIV, patients with liver disease, older adults, and those with metabolic conditions. Covers mechanisms, drug interactions, and evidence-based dosing guidance.
What the Prometrium label does and does not say about switching progestogens, with PEPI, WHI and E3N comparison data.
A complete guide to Fosamax (alendronate) regulatory history across the FDA, EMA, and major markets, including label changes, black-box warnings, and post-market safety findings.
A full regulatory history of AndroGel (testosterone gel 1% and 1.62%), from its 2000 FDA approval through post-market safety updates, label changes, and ongoing surveillance requirements.
A complete, clinically grounded look at Lipitor's FDA approval history, label changes, post-market safety updates, and what atorvastatin's regulatory record means for patients and prescribers today.
A complete regulatory and clinical overview of BPC-157: its current FDA status, compounding pharmacy classification, ongoing research pipeline, safety data, and what next-generation formulations may look like.
A complete guide to bremelanotide (Vyleesi) regulatory history, FDA-approved label details, global status, and post-market safety data. prepared by the HealthRX.com Editorial Team.
A clinician-focused review of Cialis (tadalafil) FAERS safety signals, FDA label history, post-market surveillance data, and what the adverse event database reveals about real-world risk.
A full regulatory and clinical review of epitalon tetrapeptide covering FDA status, no approved label, compounding restrictions, and published safety data from 2003 to 2026.
A complete regulatory history of oral estradiol FDA label changes from 2020 through 2026, covering boxed-warning revisions, post-market safety data, dosing guidance, and what prescribers and patients need to know today.
A comprehensive review of finasteride's FDA approval timeline, patent disputes, generic entry, label evolution, post-market safety signals, and ongoing litigation, with primary-source citations throughout.
A complete regulatory timeline of Addyi (flibanserin), including two FDA rejections, the 2015 approval, REMS requirements, labeling changes, and what the current prescribing label says about safety and dosing.
A comprehensive look at flibanserin (Addyi) regulatory history, FDA label requirements, REMS program, post-market safety data, and current availability outside the United States.
A guide to ipamorelin's regulatory status worldwide, including FDA compounding restrictions, EMA standing, and what clinicians and patients need to know before prescribing or obtaining this growth hormone secretagogue.
How the FDA and the European Medicines Agency evaluated, approved, and continue to monitor liraglutide (Victoza, Saxenda), including where the two labels genuinely diverge and where the difference is presentation rather than substance.
A complete guide to liraglutide's regulatory history across the FDA, EMA, and other agencies, including approved indications, label requirements, boxed warnings, and post-market surveillance findings.
A comprehensive look at metformin's FDA approval history, current label requirements, post-market surveillance findings, and what next-generation biguanide-class research means for clinical practice.
FDA approved Crestor on August 12, 2003 (NDA 021366) for hyperlipidemia. Covers doses, black box warning, generics since 2016, and global approvals.
A comprehensive review of Egrifta (tesamorelin) regulatory history, patent disputes, FDA labeling requirements, and post-market safety surveillance, with primary-source citations throughout.
A complete regulatory timeline of testosterone cypionate, from its 1979 FDA approval through post-market label updates, REMS requirements, and current prescribing guidance, with primary citations throughout.
A detailed look at the vaginal estradiol regulatory pipeline, current FDA-approved products, label requirements, post-market safety data, and emerging next-generation formulations in development.
A comprehensive review of vardenafil FAERS adverse-event reports, FDA label warnings, post-market surveillance data, and clinical trial safety findings for Levitra and Staxyn.
A guide to zolpidem (Ambien) global regulatory status, covering FDA approval history, current labeling requirements, international scheduling, and post-market safety actions.
Ankle swelling affects about 10.8% of users at 10mg, the most common amlodipine side effect reported by patients and confirmed in FDA data and clinical trials.
A data-driven look at AndroGel costs, real user reviews from Reddit and Drugs.com, clinical trial benchmarks, and what patients actually experience on testosterone gel therapy.
A detailed look at how Trulicity (dulaglutide) satisfaction changes from week one through year two, combining patient-reported experiences from Reddit, Drugs.com, and PatientsLikeMe with REWIND and AWARD trial data.
Finasteride response rates explained: verified regrowth and stabilization results, long-term studies, combination treatment and ways to assess your progress.
Real cost data, patient reviews, and clinical evidence for Prometrium (micronized progesterone). Learn what women on HRT actually pay, what side effects they report, and how the drug compares to synthetic progestins.
A look at what is and is not known about TB-500 user satisfaction, including what FDA found and the limited human reports.
Real cost data, user reviews, and clinical evidence for topical minoxidil 5%. Learn what patients pay out-of-pocket, what Reddit says, and what the trials actually show.
A clinical deep-dive into romosozumab's effect on liver function tests, hepatotoxicity risk, ALT/AST monitoring, and how ARCH trial data and FDA labeling inform prescribing decisions.
A guide on how to safely discontinue Rybelsus (oral semaglutide), covering tapering considerations, rebound risks, blood sugar management, and what to expect after stopping.
A guide to every documented hair and skin change associated with Rybelsus (oral semaglutide), including mechanism, incidence data, and management strategies.
A guide to oral semaglutide (Rybelsus) after bariatric surgery, covering absorption challenges, clinical evidence, dosing protocols, and safety considerations for post-bariatric patients.
MD-level protocols for traveling with Rybelsus (oral semaglutide): timezone dosing adjustments, storage during flights, altitude effects, and clinical evidence from PIONEER trials.
A guide to hair loss, skin changes, and dermatologic side effects reported with Saxenda (liraglutide 3 mg), including trial data, mechanisms, and management strategies.
Saxenda (liraglutide 3 mg) coverage varies sharply across state Medicaid programs. Learn which states cover it, how to meet prior-authorization criteria, manage step therapy, and appeal a denial.
A guide to using liraglutide 3 mg (Saxenda) after bariatric surgery, covering indications, pharmacology, dosing protocols, safety data, and the latest clinical evidence.
A clinician-level review of liraglutide 3 mg (Saxenda) safety signals, FDA label updates, post-marketing data, and risk-mitigation strategies backed by primary sources.
A guide to traveling with Saxenda (liraglutide 3 mg), covering cold-chain storage, missed-dose rules, and timezone-shift injection timing backed by primary literature.
Evidence-based sermorelin acetate dosing for adults aged 30, 49, including starting doses, titration schedules, injection technique, monitoring, and safety considerations reviewed by HealthRX.com physicians.
A clinician-level history of sermorelin acetate: how it was discovered, how it works, the key trials that shaped its use, and why it moved from FDA-approved drug to 503A compounding pharmacy staple.
Find out whether Highmark Blue Cross Blue Shield covers Viagra (sildenafil) for ED, what tier it falls on, how to get prior authorization, and how to lower your out-of-pocket cost to as little as $0.
Find out whether Oscar Health covers Cialis (tadalafil) for erectile dysfunction or BPH, what tier it sits on, how to get prior authorization, and what to do if coverage is denied.
A complete guide to Anthem's specialist referral process, including HMO vs PPO rules, authorization requirements, mental health parity, and step-by-step instructions for patients and providers.
A complete guide to Molina Healthcare's specialist referral process, including how to request a referral, which plans require authorization, timelines, and what to do if a referral is denied.
A complete guide to Blue Cross Blue Shield of Illinois coverage for Cialis (tadalafil), including formulary tiers, prior authorization requirements, cost-saving strategies, and what to do when coverage is denied.
A detailed guide to Blue Cross of Idaho's coverage policies for sildenafil (Viagra) and other ED medications, including prior authorization requirements, formulary tiers, and how to get coverage approved.